BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIOA BioAge Labs Inc.

Closed Good Friday 04-02 16:00:00 EDT

17.50

-0.23

-1.30%

盘后17.50

+0.000.00%

18:47 EDT

High18.22	Low16.99	Vol301.37K
Open16.99	D1 Closing17.73	Amplitude6.94%
Mkt Cap776.65M	Tradable Cap500.07M	Total Shares44.38M
T/O5.31M	T/O Rate1.05%	Tradable Shares28.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":17.5,"timestamp":1775160000000,"preClose":17.73,"halted":0,"volume":301370,"hourTrading":{"tag":"盘后","latestPrice":17.5,"preClose":17.5,"latestTime":"18:47 EDT","volume":7147,"amount":125069.3,"timestamp":1775170079882,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.012972363226170356,"floatShares":28575500,"shares":44379800,"eps":-2.243207,"marketStatus":"Closed Good Friday","change":-0.23,"latestTime":"04-02 16:00:00 EDT","open":16.99,"high":18.22,"low":16.99,"amount":5310182.1945400005,"amplitude":0.069374,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.243207,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":17.73,"preHourTrading":{"tag":"盘前","latestPrice":17.07,"preClose":17.73,"latestTime":"09:29 EDT","volume":604,"amount":10440.137584,"timestamp":1775136599999,"change":-0.66,"changeRate":-0.037225,"amplitude":0.031585},"postHourTrading":{"tag":"盘后","latestPrice":17.5,"preClose":17.5,"latestTime":"18:47 EDT","volume":7147,"amount":125069.3,"timestamp":1775170079882,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5261259956973237,"impliedVol":0.6409,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/BIOA/wiki","defaultTab":"wiki","newsList":[{"id":"2624966489","title":"BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624966489","media":"Reuters","labels":["shareholding","insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2624966489?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:07","pubTimestamp":1775246878,"startTime":"0","endTime":"0","summary":"BioAge Labs Chief Medical Officer Paul D. Rubin reported sale of 8,820 shares on April 1, 2026.Rubin ended day with 0 shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL8p1H5j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823007","title":"Needham Initiates BioAge Labs at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823007?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:22","pubTimestamp":1774610527,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) has an average rating of overweight and mean price target of $53.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823602","title":"Bioage Labs Inc : Needham Initiates Coverage With Buy Rating; Target Price $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823602?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:08","pubTimestamp":1774609690,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0ET:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622647823","title":"BioAge Labs Initiated at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2622647823","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622647823?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:04","pubTimestamp":1774609440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 07:04 ET (11:04 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845792","title":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845792?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:54","pubTimestamp":1774598066,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex HoldingsMarch 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOOY","GOOX","PLU","BTGO","DISO","PHAT","LBRX","GGLS","BALY","NHI","IE00BMPRXQ63.HKD","PL","MGTX","IT","GOU","FISV","OLPX","OXY","BK4561","DIS","MASI","UNX","EOG","KYIV","U","CHRD","LU0345769128.USD","OXM","PRMB","IMMX","BK4551","CTAS","CMC","LU1815333072.USD","CCL","GGLL","GOOP","BIOA","ADP","BK4134","HAL","AGX","GNRC","SPXC","KOD","FOXA","COP","GOOW","GOOGL","ATAI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622702014","title":"BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622702014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622702014?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:16","pubTimestamp":1774437366,"startTime":"0","endTime":"0","summary":"Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on BioAge Labs, Inc., retaining the price target of $23.00. Michael Ulz has given hi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bioage-labs-early-stage-promise-in-apj-agonists-balanced-by-execution-risk-supports-hold-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bioage-labs-early-stage-promise-in-apj-agonists-balanced-by-execution-risk-supports-hold-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013770","title":"BioAge Labs files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013770","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013770?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:25","pubTimestamp":1774383915,"startTime":"0","endTime":"0","summary":"16:23 EDT BioAge Labs (BIOA) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622136560","title":"Bioage Labs Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622136560","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622136560?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:23","pubTimestamp":1774383806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622136650","title":"BioAge Announces Lead Program BGE-102 NLRP3 Inhibitor Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622136650","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622136650?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:23","pubTimestamp":1774383799,"startTime":"0","endTime":"0","summary":"BioAge reported the nomination of BGE-102 as its lead program, positioning it as a potential driver for advancing the company’s pipeline in metabolic diseases.Issued patents covering composition of matter and a unique binding site were cited as an element of competitive positioning for the program.BioAge said it plans to pursue development of BGE-102 in two areas, cardiometabolic disease and ophthalmology, indicating a multi-indication commercial strategy.The company reported BGE-102 was well-tolerated in Single Ascending Dose and initial Multiple Ascending Dose cohorts, which could support continued clinical progression.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate thi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2PZktc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622904280","title":"Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622904280","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622904280?lang=en_us&edition=fundamental","pubTime":"2026-03-25 03:00","pubTimestamp":1774378837,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","BK4585","LU2324357040.USD","HCSG","BIOA","ESTA","XBI","BK4588","BK4198","LU0128526141.USD","XLV","BK4007","BK4137","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706004","title":"BioAge Highlights BGE-102 Progress and Financial Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706004","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706004?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:29","pubTimestamp":1774358989,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BioAge Labs, Inc. ( ($BIOA) ). BioAge Labs reported its full-year 2025 results and late-2025 operational milest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-highlights-bge-102-progress-and-financial-strength?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-highlights-bge-102-progress-and-financial-strength?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BIOA","BK4007","LU2065732104.USD","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621906082","title":"Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2621906082","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621906082?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:11","pubTimestamp":1774357877,"startTime":"0","endTime":"0","summary":"Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621506702","title":"BioAge Labs full-year collaboration revenue beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621506702","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621506702?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:09","pubTimestamp":1774357761,"startTime":"0","endTime":"0","summary":"BioAge Labs full-year collaboration revenue beats estimatesOverviewUS biopharmaceutical firm posts full-year collaboration revenue, beating analyst expectationsNet loss for 2025 widened as R&D and G&A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL1N40C0LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621406081","title":"Bioage Labs Q4 EPS $(0.72) Beats $(0.73) Estimate, Sales $3.078M Beat $1.915M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621406081","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621406081?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:08","pubTimestamp":1774357707,"startTime":"0","endTime":"0","summary":"Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 22.03 percent decrease over losses of $(0.59) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51430292/bioage-labs-q4-eps-0-72-beats-0-73-estimate-sales-3-078m-beat-1-915m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067442","title":"BioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067442?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:01","pubTimestamp":1774357309,"startTime":"0","endTime":"0","summary":"BioAge published a full-year earnings press release, reporting collaboration revenue of USD 9.0 million and a net loss of USD 80.6 million.Research and development expense rose 25.25% to USD 74.0 million, driven mainly by higher direct costs tied to the Novartis collaboration and BGE-102 and APJ program activities.General and administrative expense increased 44.79% to USD 27.8 million, primarily due to higher personnel-related costs, legal fees, and insurance and taxes.Cash, cash equivalents and marketable securities totaled USD 285.1 million as of Dec. 31, 2025, and management said existing resources are expected to fund operations through 2029.Clinical updates included interim Phase 1 data for BGE-102 showing an 86% median hsCRP reduction at Day 14 with 120 mg once daily, with a Phase 2a cardiovascular risk trial planned for 1H 2026 and a Phase 1b/2a diabetic macular edema study planned for mid-2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL4sb3BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","BK4112","BK4588","BK4007","NDAQ","IE00BN0W2T93.GBP","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621106709","title":"Bioage Labs Inc - Reports Positive Interim Phase 1 Data for Bge-102; Phase 2a Trial Planned in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106709?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:00","pubTimestamp":1774357207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUABJ7ZT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067187","title":"Bioage Labs Reports Full Year 2025 Financial Results and Provides Business Updates From the Fourth Quarter of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067187?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:00","pubTimestamp":1774357207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUABJ7ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067156","title":"Bioage Labs Inc FY Operating Expenses USD 101.775 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067156?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:00","pubTimestamp":1774357203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXE31C08:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621106728","title":"Press Release: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106728","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106728?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:00","pubTimestamp":1774357200,"startTime":"0","endTime":"0","summary":"Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026. Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026. Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters' overallotment option in February 2026. EMERYVILLE, Calif., March 24, 2026  -- BioAge Labs, Inc. , a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2025 and business updates for the fourth quarter ended December 31, 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620311922","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620311922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620311922?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:00","pubTimestamp":1773828000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Accenture Plc A                                  2Q      2.85   6:39 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BGSI","CURV","ARX","ELDN","MXCT","ARCO","GANX","CAL","DRI","ETON","FBRX","CUK","ACN","AIR","BZAI","ABVX","CNM","GRWG","AVAH","CDNL","BABA","DLO","ECOR","CRIS","BIOA","BZ","CNXC","ALVO","AVR","HNRG","DRIO","GEMI","GIS","CELC","AEBI","FIVE","CCL","CING","BRAG","ABSI","DERM","EVTL","FDX","FLY","EQPT","FUFU","BRZE","CLLS"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":0.0769},{"period":"1month","weight":-0.1447},{"period":"3month","weight":0.364},{"period":"6month","weight":2.1194},{"period":"1year","weight":4.0143},{"period":"ytd","weight":0.3228}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction